NCT03707535View on ClinicalTrials.gov

To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

March 16, 2020

Study Completion Date

March 5, 2021

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

CT-P13

3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid

BIOLOGICAL

Remicade

3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY